Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $44.00.

Several brokerages have recently commented on ASMB. Guggenheim reaffirmed a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a research report on Thursday, May 28th. Mizuho set a $45.00 price target on shares of Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. Wall Street Zen cut shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a report on Monday, May 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Monday, April 20th.

Institutional Investors Weigh In On Assembly Biosciences

A number of large investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its stake in shares of Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,319 shares in the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Assembly Biosciences during the 4th quarter worth about $147,000. Acadian Asset Management LLC grew its holdings in Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in Assembly Biosciences during the fourth quarter valued at approximately $228,000. Finally, Virtus Investment Advisers LLC acquired a new position in Assembly Biosciences during the fourth quarter valued at approximately $251,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Stock Down 5.3%

Shares of Assembly Biosciences stock opened at $24.26 on Friday. The stock has a market cap of $385.49 million, a PE ratio of -220.53 and a beta of 1.07. The business has a fifty day simple moving average of $26.83 and a 200-day simple moving average of $28.73. Assembly Biosciences has a 12 month low of $16.81 and a 12 month high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.11. The business had revenue of $8.21 million during the quarter, compared to analysts’ expectations of $9.27 million. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%. Analysts expect that Assembly Biosciences will post 1.9 EPS for the current fiscal year.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.